Publications by authors named "Timothy Burns"

Claim this Profile
M
MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype.
Timothy F Burns, Sanja Dacic, Anish Chakka, Ethan Miller, Maria A Velez

J Clin Invest· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).
Liza C Villaruz, Jingxiao Jin, Hong Wang, James J Lee, Jason J Luke, Timothy F Burns

Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC.
Timothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, Dae Ho Lee, Takafumi Koyama

J Thorac Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous Retroperitoneal Haemorrhage From Bilateral Renal Angiomyolipomas: A Case Report on a First Presentation of Tuberous Sclerosis Complex.
Christian J Kirk, Timothy Burns, Flavio Ordones, Wikus Vermeulen

Cureus· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-Resolved Crystallography Reveals the Mechanisms of GTP hydrolysis for N-RAS and the Oncogenic Mutants G12C, G12V and Q61L.
Guowu Lin, Paola Zinser-Peniche, Xiaohong Zhou, Ulises Santiago, Igor Kurnikov, Timothy F Burns

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the treatment of KRAS mutant non-small cell lung cancer.
Khvaramze Shaverdashvili, Timothy F Burns

Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
Mitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, Leora Horn, D Ross Camidge

Clin Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced hierarchical computational modeling-based rational development of platinum (II) nanocomplex to improve lung cancer therapy.
Haozhe Huang, Beihong Ji, Yixian Huang, Shichen Li, Zhangyi Luo, Timothy F Burns

Adv Funct Mater· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells" [Neoplasia 17 (2014) 85].
Rajendra P Gajula, Sivarajan T Chettiar, Russell D Williams, Katriana Nugent, Yoshinori Kato, Timothy F Burns

Neoplasia· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma.
Suet Kee Loo, Gabriel Sica, Xian Wang, Tingting Li, Luping Chen, Timothy F Burns

Cell Biosci· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases.
Xiancheng Wu, Laura P Stabile, Timothy F Burns

Clin Lung Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The landscape of perioperative immunotherapy in non-small cell lung cancer: what have we learned from the AEGEAN trial?
Jingxiao Jin, Timothy F Burns

Chin Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-driven decision support: A community-based meta-implementation strategy to predict population impact.
Kimberly Johnson, Wouter Vermeer, Holly Hills, Lia Chin-Purcell, Joshua T Barnett, Timothy Burns

Ann Epidemiol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon, Timothy F Burns

Cancer Res Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer.
Vinod Kumar, Zachary A Yochum, Princey Devadassan, Eric H-B Huang, Ethan Miller, Timothy F Burns

Oncogene· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 Testing Among Out-of-Hospital Cardiac Arrest Patients: Implications for Public Health.
Roger M Stone, Benjamin T Kaufman, Timothy A Burns, Theodore R Delbridge

Prehosp Emerg Care· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Path to Persistence after EGFR Inhibition.
Purva H Rumde, Timothy F Burns

Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer.
Abdulkader Yassin-Kassab, Suman Chatterjee, Nayel Khan, Nathaniel Wang, Vlad C Sandulache, Timothy F Burns

BMC Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
James N Gerson, Elizabeth Handorf, Diego Villa, Alina S Gerrie, Parv Chapani, Timothy Burns

Blood Adv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the epidermal growth factor receptor following complete surgical resection in patients with early-stage non-small cell lung cancer.
Khvaramze Shaverdashvili, Timothy F Burns

Expert Opin Pharmacother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution.
Jaime L Schneider, Khvaramze Shaverdashvili, Mari Mino-Kenudson, Subba R Digumarthy, Andrew Do, Timothy F Burns

NPJ Precis Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Male sex and pretreatment weight loss are associated with poor outcome in patients with advanced non-small cell lung cancer treated with immunotherapy: a retrospective study.
Jingxiao Jin, Jacqueline Visina, Timothy F Burns, Brenda Diergaarde, Laura P Stabile

Sci Rep· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).
Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Timothy F Burns

Clin Cancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial Comment.
Timothy J Burns, Peter J Gilling

J Urol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Device evaluation: eCoin #x2013; implantable tibial nerve stimulator for overactive bladder.
Morgan J Bressington, David Scholtz, Ali Hooshiary, Wikus Vermeulen, Timothy Burns

Expert Rev Med Devices· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis